NVAX FY 2020 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$22M+20.0% YoY

Gross Profit

$22M100.0% margin

Operating Income

-$417M-1861.3% margin

Net Income

-$418M-1868.2% margin

EPS (Diluted)

$-7.43

Cash Flow

Operating Cash Flow

-$43M

Free Cash Flow

-$97M

Stock-Based Comp.

$128M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$955M

Stockholders' Equity

$627M

Cash & Equivalents

$553M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$22M	$19M	+20.0%
Gross Profit	$22M	-$95M	+123.5%
Operating Income	-$417M	-$121M	-245.6%
Net Income	-$418M	-$130M	-221.5%